Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00534209 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy
A Phase 1 study, sponsored by University of Miami.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT00534209: Clinical Trial Phase 1 study, sponsored by University of Miami.
NCT00534209 is a Phase 1 study that was terminated before completion, run by University of Miami. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00534209, a Phase 1 study, was terminated before completion, sponsored by University of Miami.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with stage IIIB or stage IV non-small cell lung cancer who have finished first-line chemotherapy.
Primary Outcome
This will include the number of patients experiencing toxicity over the course of treatment, characterized by type of toxicity and grade, and by the time of toxicity onset in relation to day of vaccination.
Interventions
- OTHER Placebo
- BIOLOGICAL Allogeneic B7.1/HLA-A1
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-01 |
| Est. Completion | 2010-04 |
| Phase | Phase 1 |
Why NCT00534209 stopped before completion
NCT00534209 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00534209 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00534209 about?
NCT00534209 is a clinical study titled "Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy". RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with stage IIIB or stage IV non-small c...
What is the current status of trial NCT00534209?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2009-01. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00534209?
The interventions under investigation include: Placebo (OTHER), Allogeneic B7.1/HLA-A1 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00534209?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00534209's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia